Sarepta Therapeutics, Inc. Share Price & Technical Analysis
SRPT · $15.89 (+2.19%)
Healthcare / Biotechnology
$15.89
+2.19%
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skip…
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-10% return in Jun, -13% avg return in past 3 year Jun month.
-18% return in 2026, -37% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -7% | -16% | 34% | -5% | -14% | -10% | – | – | – | – | – | – | -18% |
| 25 | -7% | -4% | -40% | -3% | -40% | -55% | -4% | 13% | 7% | 27% | -12% | 3% | -116% |
| 24 | 25% | 7% | 2% | -2% | 2% | 23% | -10% | -5% | -8% | 1% | 6% | -8% | 32% |
| 23 | -3% | -2% | -4% | -10% | 1% | -7% | -5% | 12% | 0% | -44% | 19% | 19% | -26% |
| 22 | -21% | 7% | 3% | -8% | 1% | 3% | 25% | 18% | 1% | 3% | 7% | 6% | 46% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.65B
P/E ratio
44.74
52W high
$39.64
52W low
$10.42
Volume
18,63,164
Beta
0.20
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Sarepta Therapeutics, Inc. share price today?
- Sarepta Therapeutics, Inc. (SRPT) last traded around $15.89 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SRPT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SRPT. Download the app for real-time alerts.
- How can I analyze Sarepta Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.